/Investor DB

Orlando Health Ventures — 2023 Investments

2 investments dated 2023 · listed companies and verified rows first · show all

Arrivo BioVenturesarrivobio.cominNov 2023✓ verified

Arrivo Bio develops novel, disease-modifying medicines targeting the root cause of hard-to-treat diseases for which few effective treatment options exist.

BiotechMedical DevicesMorrisville, US

Karen Adams(Executive Officer)Stephen E. Butts(Executive Officer)

Co-investorsRex Health VenturesSolas BioVentures

Sensydiasensydia.comin𝕏May 2023 · $8M

Sensydia develops non-invasive wireless cardiac monitoring technology using machine learning to diagnose and manage heart disease.

AI & Machine LearningHardwareHealthtechMedical DevicesLos Angeles, US

Anthony Arnold(CEO)inDr. Aman Mahajan(CMO)inRusty Page(President & COO)inKanav Saraf(Executive Officer)Erick Hawkins(Director)Victroia K. Grace(Director)

Co-investorsColle Capital PartnersFrontier Venture Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.